Skip to main content

Table 1 Distribution of clinical and epidemiological characteristics of the 113 patients included in the historical cohort and univariate analysis of risk

From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

Cohort description Univariate risk analysis
Patients’ features Distribution N. of events Person-days at risk Rate (95%CI) RR (95%CI) p-value
Sex Male 65 (57.52%) 121 32675 3.70 (2.71-5.19) 1.00  
Female 48 (42.48%) 60 22248 2.70 (1.71-4.50) 0.73 (0.38-1.40) 0.342
Age <60 60 (53.10%) 127 29824 4.26 (3.16-5.86) 1.00  
60 or more 53 (47.90%) 54 25099 2.15 (1.33-3.70) 0.49 (0.26-0.93) 0.028
Nadir A ≥ 0.13 ×109 /L 85 (75.22%) 104 41183 2.53 (1.82-3.59) 1.00  
<0.13 ×109 /L 28 (24.78%) 77 1374 5.60 (3.83-8.51) 2.04 (1.02-4.05) 0.042
GVHD No 98 (86.73%) 141 47756 2.95 (2.20-4.06) 1.00  
Yes 15 (13.27%) 40 7167 5.58 (3.38-9.79) 2.18 (0.88-5.44) 0.090
HIV Neg 103 (91.15%) 153 50914 3.01 (2.28-4.05) 1.00  
Pos 10 (8.85%) 28 4009 6.98 (3.45-15.35) 3.13 (1.06-9.24) 0.039
Relapse No 93 (82.30%) 138 45537 3.03 (2.27-4.13) 1.00  
Yes 20 (17.70%) 43 9386 4.58 (2.56-8.92) 1.81 (0.79-4.15) 0.163
Protocol R alone 20 (17.70%) 25 10362 2.41 (1.26-5.26) 1.00  
R and CHT 56 (49.56%) 69 25417 2.71 (1.76-4.37) 1.60 (0.68-3.77)  
R and auto HSCT 10 (8.85%) 11 545 2.02 (0.69-8.49) 0.84 (0.24-2.93)  
R and allo HSCT 27 (23.89%) 76 13694 5.55 (3.85-8.27) 2.73 (1.08-6.94) 0.102
Disease Indolent lymph. B 43 (38.05%) 45 21934 2.05 (1.28-3.50) 1.00  
Aggressive lymph. C 53 (46.90%) 97 25188 3.85 (2.67-5.72) 2.31 (1.18-4.54)  
Non-CD20 malig. D 17 (15.05%) 39 7801 5.00 (2.92-9.23) 2.95 (1.16-7.53) 0.024
Time 1st semester 113 E 108 18999 5.68 (4.20-7.89) 1.00 <0.001
2nd semester 99 E 40 18018 2.22 (1.43-3.65) 0.43 (0.30-0.63)
3rd semester 99 E 33 17906 1.84 (1.08-3.41) 0.36 (0.24-0.53)
Median R doses (iqr) 4 (2–6) - - - 0.95 (0.84-1.08) 0.471
Mean days between doses (iqr) 17 (9–19) - - - 0.99 (0.97-1.02) 0.664
Median days with <1000 ly (iqr) 38 (0–220) - - - 1.00 (1.00-1.00) 0.946
Overall 113 (100%) 181 54923 3.30 (2.54-4.34)   
  1. N number, HSCT hematopoietic stem cells transplant, HIV antibody against human immunodeficiency virus, GVHD graft versus host disease, R Rituximab, CHT chemotherapy, IQR inter-quartile range, RR rate ratio, 95%CI 95% confidence interval.
  2. A) 0.13x109/L lymphocytes represents the lowest quartiles limit; B) This includes: 19 follicular lymphomas; 11 chronic lymphatic leukaemias; 6 lymphoplasmacytic lymphomas; 3 mantle cell lymphomas; 2 multiple myelomas; 2 marginal zone lymphomas. C) This includes: 30 diffuse large cell B lymphomas; 8 acute lymphatic leukemias/lymphomas; 7 Burkitt's lymphomas; 4 post transplant lymphomatous diseases; 2 primary central nervous system lymphomas; 2 Castleman's diseases. D) This includes: 11 myeloid leukaemias, 5 Hodgkin lymphomas, 1 T-lymphoma; E) The figure represent the number of patients at the start of the semester since the first R administration.